Stebner Alexander, Bosshart Salome, Hainc Nicolin, Nierobisch Nathalie, Zedde Marialuisa, Pascarella Rosario, Goyal Mayank, Ospel Johanna
Department of Diagnostic Imaging, Foothills Medical Centre, University of Calgary, Canada.
Department of Clinical Neurosciences, Foothills Medical Centre, University of Calgary, Canada.
Ann Indian Acad Neurol. 2024 Jul 1;27(4):403-407. doi: 10.4103/aian.aian_548_24. Epub 2024 Aug 22.
Contrast-induced encephalopathy (CIE) is a rare adverse event linked to intravascular use of iodine-containing contrast media. The prevalence of CIE could increase in the future due to growing numbers of endovascular procedures. We provide insights from a case series of 7 patients.
Cases from 3 centers were collected based on existing academic collaborations, and key factors were extracted to illustrate development and management of CIE.
In our retrospective case-series analysis of 7 cases from 3 countries, affected patients had an equal distribution of sex (4 women, 3 men) and a median age of 75 (IQR 63-77). Common risk factors included hypertension (5/7), hyperlipidemia (5/7), previous stroke (3/7), and type 2 diabetes (3/7). CIE developed in 3 cases after endovascular thrombectomy (EVT) for stroke, in 2 cases after aneurysm treatment, in 1 case after cardiac catheterization, and in 1 case after diagnostic computed tomography (CT) angiography without an endovascular procedure. The median procedure time was 48 min (IQR 40-81). All patients received non-ionic, low-osmolar contrast agents with volumes ranging from 100-300 ml. Symptom onset was close to contrast administration, with stroke-like neurological deficits being most common (4/7). Prednisolone was the most frequently used medication to treat the symptoms (4/7). Symptom resolution occurred in 4 out of 7 patients within two to several days, and 1 patient died, but without clear connection to CIE.
CIE is a rare and possibly underrecognized condition, but fortunately, with a favorable outcome in most cases.
对比剂诱发的脑病(CIE)是一种与血管内使用含碘对比剂相关的罕见不良事件。由于血管内手术数量的增加,CIE的患病率未来可能会上升。我们提供了7例病例系列的见解。
基于现有的学术合作收集了3个中心的病例,并提取关键因素以说明CIE的发生和管理。
在我们对来自3个国家的7例病例的回顾性病例系列分析中,受影响患者的性别分布均衡(4名女性,3名男性),中位年龄为75岁(四分位间距63 - 77岁)。常见风险因素包括高血压(5/7)、高脂血症(5/7)、既往中风(3/7)和2型糖尿病(3/7)。3例CIE发生在中风的血管内血栓切除术(EVT)后,2例发生在动脉瘤治疗后,1例发生在心脏导管插入术后,1例发生在无血管内手术的诊断性计算机断层扫描(CT)血管造影术后。中位手术时间为48分钟(四分位间距40 - 81分钟)。所有患者均接受了非离子型、低渗对比剂,用量在100 - 300毫升之间。症状发作接近对比剂给药时间,中风样神经功能缺损最为常见(4/7)。泼尼松龙是最常用于治疗症状的药物(4/7)。7例患者中有4例在两到几天内症状缓解,1例患者死亡,但与CIE无明确关联。
CIE是一种罕见且可能未被充分认识的疾病,但幸运的是,大多数情况下预后良好。